# RadSABR (NCT03304418)

> Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

No report yet. It can be ordered.

- Drugs tested: radium-223
- Indication: hormone-naïve oligometastatic prostate cancer to bone

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03304418
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: University of Utah
- Conditions: Prostate Cancer Metastatic to Bone
- Interventions: Radium Ra 223 Dichloride; Radiation
- Enrollment: 20
- Primary outcome: Count of Participants Requiring Androgen Deprivation Therapy (ADT) Use at 15 Months

## Indexed commentary on RadSABR so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=radsabr-nct03304418